Bottom line
PHSTX vs RYHIX: the short answer
PHSTX (Putnam Global Health Care Fund) and RYHIX (Health Care Fund) are both mutual funds.
PHSTX is cheaper at 1.04% vs 1.38% — a difference of $34 a year per $10,000 invested.
Over five years, PHSTX returned +6.5% a year vs +5.1% for RYHIX (reporting dates differ).
PHSTX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
PHSTX vs RYHIX side by side
| PHSTX | RYHIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.04% | 1.38% |
| Annual cost per $10k | $104 | $138 |
| 10-yr cost on $10k (prospectus) | $1,772 | $1,709 |
| Max front load | 5.75% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −4.6% | +14.4% |
| 5-yr return (annualized) | +6.5% | +5.1% |
| 10-yr return (annualized) | +6.9% | +7.9% |
| Best quarter | +17.5% | +18.7% |
| Worst quarter | −12.3% | −14.4% |
| Net assets (fund) | $1.5B | $19.4M |
| Number of holdings | 115 | 135 |
| Portfolio turnover | 67% | 244% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSTX | RYHIX | Difference |
|---|---|---|---|
| 2024 | +1.3% | +0.6% | +0.7% |
| 2023 | +9.0% | +5.8% | +3.2% |
| 2022 | −4.7% | −11.6% | +6.9% |
| 2021 | +19.4% | +19.2% | +0.2% |
| 2020 | +15.9% | +18.9% | −3.0% |
| 2019 | +30.2% | +22.8% | +7.5% |
| 2018 | −0.6% | +1.6% | −2.2% |
| 2017 | +15.3% | +23.5% | −8.2% |
| 2016 | −11.7% | −9.4% | −2.3% |
Source: Fund prospectus bar charts
Holdings overlap
17 of PHSTX's top 25 holdings also appear in RYHIX's top 25.
| Holding | PHSTX | RYHIX |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 3.63% |
| Johnson & Johnson | 8.46% | 2.88% |
| UnitedHealth Group, Inc. | 6.93% | 2.22% |
| AbbVie, Inc. | 6.05% | 2.52% |
| Merck & Co., Inc. | 4.88% | 2.04% |
| Thermo Fisher Scientific, Inc. | 4.50% | 1.61% |
| Intuitive Surgical, Inc. | 4.04% | 1.31% |
| Edwards Lifesciences Corp. | 2.80% | 0.84% |
| CVS Health Corp. | 2.74% | 1.31% |
| Gilead Sciences, Inc. | 2.63% | 1.39% |
| McKesson Corp. | 2.14% | 1.05% |
| Cardinal Health, Inc. | 2.12% | 0.86% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 1.34% |
| Boston Scientific Corp. | 1.80% | 0.86% |
| Bristol-Myers Squibb Co. | 1.75% | 1.22% |
Source: SEC Form N-PORT
PHSTX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between PHSTX and RYHIX?
Which is cheaper, PHSTX or RYHIX?
Should I own both PHSTX and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.